250 related articles for article (PubMed ID: 31628266)
21. Immunoconjugates and new molecular targets in hairy cell leukemia.
Kreitman RJ
Hematology Am Soc Hematol Educ Program; 2012; 2012():660-6. PubMed ID: 23233649
[TBL] [Abstract][Full Text] [Related]
22. Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.
Wayne AS; Shah NN; Bhojwani D; Silverman LB; Whitlock JA; Stetler-Stevenson M; Sun W; Liang M; Yang J; Kreitman RJ; Lanasa MC; Pastan I
Blood; 2017 Oct; 130(14):1620-1627. PubMed ID: 28983018
[TBL] [Abstract][Full Text] [Related]
23. Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib.
Paillassa J; Safa F; Troussard X
Ther Adv Hematol; 2022; 13():20406207221090886. PubMed ID: 35450208
[TBL] [Abstract][Full Text] [Related]
24. The pharmacological management of hairy cell leukemia.
Ramos Perez J; Ravandi-Kashani F
Expert Opin Pharmacother; 2020 Aug; 21(11):1337-1344. PubMed ID: 32378970
[TBL] [Abstract][Full Text] [Related]
25. Management of Relapsed Hairy Cell Leukemia: A Systematic Review of Novel Agents and Targeted Therapies.
Siddiqui R; Sardar M; Shahzad M; Jose J; Selene I; Shah Z; Qureshi A; Shafqat M; Kashif R; Ahmad M; Mejia-Garcia A; Anwer F
Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):659-666. PubMed ID: 34275772
[TBL] [Abstract][Full Text] [Related]
26. Moxetumomab Pasudotox: First Global Approval.
Dhillon S
Drugs; 2018 Nov; 78(16):1763-1767. PubMed ID: 30357593
[TBL] [Abstract][Full Text] [Related]
27. No Loose Ends: A Review of the Pharmacotherapy of Hairy Cell and Hairy Cell Leukemia Variant.
King AC; Kabel CC; Pappacena JJ; Stump SE; Daley RJ
Ann Pharmacother; 2019 Sep; 53(9):922-932. PubMed ID: 30841702
[No Abstract] [Full Text] [Related]
28. Hairy Cell Leukemia (HCL) and HCL Variant: Updates and Spotlights on Therapeutic Advances.
Paillassa J; Maitre E; Troussard X
Curr Oncol Rep; 2022 Sep; 24(9):1133-1143. PubMed ID: 35403971
[TBL] [Abstract][Full Text] [Related]
29. Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia.
Tiacci E; De Carolis L; Simonetti E; Capponi M; Ambrosetti A; Lucia E; Antolino A; Pulsoni A; Ferrari S; Zinzani PL; Ascani S; Perriello VM; Rigacci L; Gaidano G; Della Seta R; Frattarelli N; Falcucci P; Foà R; Visani G; Zaja F; Falini B
N Engl J Med; 2021 May; 384(19):1810-1823. PubMed ID: 33979489
[TBL] [Abstract][Full Text] [Related]
30. Bendamustine and rituximab in relapsed and refractory hairy cell leukemia.
Burotto M; Stetler-Stevenson M; Arons E; Zhou H; Wilson W; Kreitman RJ
Clin Cancer Res; 2013 Nov; 19(22):6313-21. PubMed ID: 24097860
[TBL] [Abstract][Full Text] [Related]
31. [Moxetumomab pasudotox-Third line in Hairy cell leukemia].
Montes L; Herbaux C
Bull Cancer; 2021 Dec; 108(12):1073-1074. PubMed ID: 34776118
[No Abstract] [Full Text] [Related]
32. Refractory and relapsed hairy-cell leukemia (HCL): casting light on promising experimental drugs in clinical trials.
Robak T; Robak P
Expert Opin Investig Drugs; 2023 Apr; 32(4):311-324. PubMed ID: 36931901
[TBL] [Abstract][Full Text] [Related]
33. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
34. Novel therapeutic options for relapsed hairy cell leukemia.
Jain P; Polliack A; Ravandi F
Leuk Lymphoma; 2015; 56(8):2264-72. PubMed ID: 25563425
[TBL] [Abstract][Full Text] [Related]
35. Responses in refractory hairy cell leukemia to a recombinant immunotoxin.
Kreitman RJ; Wilson WH; Robbins D; Margulies I; Stetler-Stevenson M; Waldmann TA; Pastan I
Blood; 1999 Nov; 94(10):3340-8. PubMed ID: 10552943
[TBL] [Abstract][Full Text] [Related]
36. How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors.
Falini B; De Carolis L; Tiacci E
Blood; 2022 Apr; 139(15):2294-2305. PubMed ID: 35143639
[TBL] [Abstract][Full Text] [Related]
37. Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia.
Shah NN; Bhojwani D; August K; Baruchel A; Bertrand Y; Boklan J; Dalla-Pozza L; Dennis R; Hijiya N; Locatelli F; Martin PL; Mechinaud F; Moppett J; Rheingold SR; Schmitt C; Trippett TM; Liang M; Balic K; Li X; Vainshtein I; Yao NS; Pastan I; Wayne AS
Pediatr Blood Cancer; 2020 May; 67(5):e28112. PubMed ID: 31944549
[TBL] [Abstract][Full Text] [Related]
38. New treatment options in hairy cell leukemia with focus on BRAF inhibitors.
Falini B; Tiacci E
Hematol Oncol; 2019 Jun; 37 Suppl 1():30-37. PubMed ID: 31187521
[TBL] [Abstract][Full Text] [Related]
39. Potential breakthroughs with investigational drugs for hairy cell leukemia.
Robak T; Wolska A; Robak P
Expert Opin Investig Drugs; 2015; 24(11):1419-31. PubMed ID: 26329588
[TBL] [Abstract][Full Text] [Related]
40. Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia.
Chihara D; Arons E; Stetler-Stevenson M; Yuan CM; Wang HW; Zhou H; Raffeld M; Xi L; Steinberg SM; Feurtado J; James L; Wilson W; Braylan RC; Calvo KR; Maric I; Dulau-Florea A; Kreitman RJ
J Clin Oncol; 2020 May; 38(14):1527-1538. PubMed ID: 32109194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
